European Pharmaceutical Review

FEBRUARY 27, 2024

The Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), Dame June Raine, will step down in the Autumn following five years in the role. While she is stepping down from her current role, Dame June shared that she still hopes to contribute “to patient safety and public health in other ways.”

Pharmacology 92

Pharmacology Safety Medicine Education 92

Pharmaceutical Technology

SEPTEMBER 14, 2022

Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacological leads are being investigated worldwide, across various phases of development. Discover the top API protein and peptide companies in contract marketing.

Leads 52

Leads Marketing Pharmacology Retail 52

European Pharmaceutical Review

JULY 13, 2023

While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful. This could lead to significant research waste. Expert Review of Clinical Pharmacology. British journal of pharmacology.

Medical 83

Medical Food and Drug Administration Pharmacology Medicine 83

European Pharmaceutical Review

MARCH 11, 2024

HIV treatment and prevention are at an inflection point after years of continuously improving the standard of care of once-daily oral medicines. Our industry is on the cusp of the next wave of medicines that will guide the coming decade of HIV care, making HIV a smaller part of people’s lives. 3 But that paradigm is rapidly changing.

Medicine 88

Medicine Pharmacology Healthcare Healthcare 88

European Pharmaceutical Review

MAY 2, 2023

Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. 3 With greater scientific understanding of cancer, the industry has made significant progress in developing innovative medicines to help patients. 1,2 In the EU, an estimated 2.7

Patients 98

Patients Medicine Marketing Medical 98

European Pharmaceutical Review

JULY 27, 2023

Cardiovascular diseases are the leading cause of death globally with over 18.5 Cardiovascular diseases are the leading cause of death globally with over 18.5 Despite these trials varying in design, they confirmed the feasibility and safety of the procedure. 1 Furthermore, there are 63.3 1 Furthermore, there are 63.3

Pharmacology 89

Pharmacology Manufacturing Leads Patients 89

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5

Food and Drug Administration 75

Food and Drug Administration Safety Patients Leads 75